Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
- PMID: 28285592
- PMCID: PMC5346853
- DOI: 10.1186/s12916-017-0819-3
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Erratum in
-
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?BMC Med. 2017 Apr 20;15(1):82. doi: 10.1186/s12916-017-0857-x. BMC Med. 2017. PMID: 28427399 Free PMC article. No abstract available.
Abstract
The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new reflex biomarker for guiding first-line treatment in patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of immune checkpoint inhibitors and chemotherapy as the first-line treatment; however, this strategy has not yet been validated by phase III trial data and its interplay with PD-L1 status still requires clarification.In this manuscript we review the contradictory results of recent phase III trials with immune checkpoint inhibitors in the first-line setting, the potential reasons for discrepancies, and some of the remaining open questions related to the positioning of immune checkpoint inhibitors in the first-line setting of non-small cell lung cancer.
Keywords: First-line; Immunotherapy; Nivolumab; Non-small cell lung cancer; PD-1; PD-L1; Pembrolizumab.
Figures
Similar articles
-
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6. Lung Cancer. 2017. PMID: 28285697 Review.
-
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.Future Oncol. 2016 Aug;12(15):1805-22. doi: 10.2217/fon-2016-0086. Epub 2016 Jun 8. Future Oncol. 2016. PMID: 27267211 Review.
-
Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.BioDrugs. 2016 Oct;30(5):397-405. doi: 10.1007/s40259-016-0187-0. BioDrugs. 2016. PMID: 27411930 Review.
-
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16. Clin Lung Cancer. 2017. PMID: 28416123 Review.
-
[Immune checkpoint inhibitors in lung cancer].Internist (Berl). 2020 Jul;61(7):676-681. doi: 10.1007/s00108-020-00815-y. Internist (Berl). 2020. PMID: 32462250 Review. German.
Cited by
-
Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis.Front Oncol. 2023 Aug 9;13:1176574. doi: 10.3389/fonc.2023.1176574. eCollection 2023. Front Oncol. 2023. PMID: 37621675 Free PMC article.
-
Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.Cells. 2023 Jun 23;12(13):1702. doi: 10.3390/cells12131702. Cells. 2023. PMID: 37443736 Free PMC article. Review.
-
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.J Immunother Cancer. 2023 Jan;11(1):e005801. doi: 10.1136/jitc-2022-005801. J Immunother Cancer. 2023. PMID: 36650021 Free PMC article.
-
The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors.Front Pharmacol. 2022 Oct 18;13:910722. doi: 10.3389/fphar.2022.910722. eCollection 2022. Front Pharmacol. 2022. PMID: 36330095 Free PMC article.
-
Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.Front Oncol. 2022 Aug 3;12:939022. doi: 10.3389/fonc.2022.939022. eCollection 2022. Front Oncol. 2022. PMID: 35992799 Free PMC article.
References
-
- Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S, ESMO Guidelines Committee Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–v27. doi: 10.1093/annonc/mdw326. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials